MDM2 and acute myeloid leukemia: Idasanutlin (RG7388) with more potency, selectivity, and better pharmacokinetic profile than other MDM2 inhibitors appears interesting in preclinical assays, is tested in clinical trials for acute myeloid leukemia and recently in the N2M2 (NOA-20) clinical trials in GBM (NCT01358389) [71].